The role of mutations in epigenetic regulators in myeloid malignancies (original) (raw)

• Byrd, J. C. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325–4336 (2002).
  Article CAS PubMed Google Scholar
• Schlenk, R. F. et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1909–1918 (2008).
  Article CAS PubMed Google Scholar
• Gilliland, D. G. Hematologic malignancies. Curr. Opin. Hematol. 8, 189–191 (2001).
  Article CAS PubMed Google Scholar
• Goldberg, A. D., Allis, C. D. & Bernstein, E. Epigenetics: a landscape takes shape. Cell 128, 635–638 (2007).
  Article CAS PubMed Google Scholar
• Florean, C., Schnekenburger, M., Grandjenette, C., Dicato, M. & Diederich, M. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 3, 581–609 (2011).
  Article CAS PubMed Google Scholar
• Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079–1089 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Mikkelsen, T. S. et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553–560 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Cedar, H. & Bergman, Y. Epigenetics of haematopoietic cell development. Nature Rev. Immunol. 11, 478–488 (2011).
  Article CAS Google Scholar
• Ji, H. et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 467, 338–342 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Borgel, J. et al. Targets and dynamics of promoter DNA methylation during early mouse development. Nature Genet. 42, 1093–1100 (2010).
  Article CAS PubMed Google Scholar
• Faber, J. et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113, 2375–2385 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Figueroa, M. E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13–27 (2010). A study demonstrating subclassification of AML through systematic methylation profiling.
  Article CAS PubMed PubMed Central Google Scholar
• Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2433 (2010). Identification of DNMT3A mutations in AML by large-scale sequencing.
  Article CAS PubMed PubMed Central Google Scholar
• Thol, F. et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J. Clin. Oncol. 29, 2889–2896 (2011).
  Article CAS PubMed Google Scholar
• Gowher, H. et al. Mutational analysis of the catalytic domain of the murine Dnmt3a DNA-(cytosine C5)-methyltransferase. J. Mol. Biol. 357, 928–941 (2006).
  Article CAS PubMed Google Scholar
• Yamashita, Y. et al. Array-based genomic resequencing of human leukemia. Oncogene 29, 3723–3731 (2010).
  Article CAS PubMed Google Scholar
• Yan, X. J. et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genet. 43, 309–315 (2011).
  Article CAS PubMed Google Scholar
• Fried, I. et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica 97, 246–250 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Chedin, F. The DNMT3 family of mammalian de novo DNA methyltransferases. Prog. Mol. Biol. Transl. Sci. 101, 255–285 (2011).
  Article CAS PubMed Google Scholar
• Ooi, S. K. et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448, 714–717 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Tadokoro, Y., Ema, H., Okano, M., Li, E. & Nakauchi, H. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J. Exp. Med. 204, 715–722 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Challen, G. A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genet. 44, 23–31 (2012).
  Article CAS Google Scholar
• Ono, R. et al. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 62, 4075–4080 (2002).
  CAS PubMed Google Scholar
• Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009).
  Article PubMed Google Scholar
• Langemeijer, S. M. et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genet. 41, 838–842 (2009). References 25 and 26 first identified TET2 mutations in myeloid malignancies.
  Article CAS PubMed Google Scholar
• Metzeler, K. H. et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 29, 1373–1381 (2011).
  Article PubMed PubMed Central Google Scholar
• Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496–2506 (2011). A large clinical study that reported the clinical implications of somatic mutations in epigenetic modifiers in MDS.
  Article CAS PubMed PubMed Central Google Scholar
• Abdel-Wahab, O. et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 70, 447–452 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Schaub, F. X. et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115, 2003–2007 (2010).
  Article CAS PubMed Google Scholar
• Smith, A. E. et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116, 3923–3932 (2010).
  Article CAS PubMed Google Scholar
• Valinluck, V. et al. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 32, 4100–4108 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Pastor, W. A. et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473, 394–397 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Valinluck, V. & Sowers, L. C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 67, 946–950 (2007).
  Article CAS PubMed Google Scholar
• Guo, J. U., Su, Y., Zhong, C., Ming, G. L. & Song, H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145, 423–434 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Boorstein, R. J. et al. Definitive identification of mammalian 5-hydroxymethyluracil DNA N-glycosylase activity as SMUG1. J. Biol. Chem. 276, 41991–41997 (2001).
  Article CAS PubMed Google Scholar
• Bennett, M. T. et al. Specificity of human thymine DNA glycosylase depends on N-glycosidic bond stability. J. Am. Chem. Soc. 128, 12510–12519 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303–1307 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, H. et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev. 25, 679–684 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Yildirim, O. et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147, 1498–1510 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ficz, G. et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 473, 398–402 (2011).
  Article CAS PubMed Google Scholar
• Wu, H. & Zhang, Y. Tet1 and 5-hydroxymethylation: a genome-wide view in mouse embryonic stem cells. Cell Cycle 10, 2428–2436 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839–843 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11–24 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kosmider, O. et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 94, 1676–1681 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25–38 (2011).
  Article CAS PubMed Google Scholar
• Li, Z. et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118, 4509–4518 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058–1066 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Marcucci, G. et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 28, 2348–2355 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339–344 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Akalin, A. et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet. 8, e1002781 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17–30 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010). References 54 and 55 identify the functional interaction between IDH1 and IDH2 mutations and TET enzymes.
  Article CAS PubMed PubMed Central Google Scholar
• Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 4 Jul 2012 (doi:10.1038/nature11323).
• McDonough, M. A., Loenarz, C., Chowdhury, R., Clifton, I. J. & Schofield, C. J. Structural studies on human 2-oxoglutarate dependent oxygenases. Curr. Opin. Struct. Biol. 20, 659–672 (2010).
  Article CAS PubMed Google Scholar
• Chowdhury, R. et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463–469 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Koivunen, P. et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484–488 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Losman, J.-A., Lee, S., Koivunen, P., Looper, R. E. & Kaelin, W. G. Enantiomer-specific transformation by 2HG is linked to opposing effects on α-ketoglutarate-dependent dioxygenases. Blood (ASH Annual Meeting Abstracts) 118, LBA-4 (2011).
  Google Scholar
• Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bracken, A. P. et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323–5335 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).
  Article CAS PubMed Google Scholar
• Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695–1699 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genet. 42, 181–185 (2010).
  Article CAS PubMed Google Scholar
• Sneeringer, C. J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980–20985 (2010).
  Article PubMed PubMed Central Google Scholar
• Yu, J. et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67, 10657–10663 (2007).
  Article CAS PubMed Google Scholar
• Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genet. 42, 722–726 (2010).
  Article CAS PubMed Google Scholar
• Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genet. 42, 665–667 (2010).
  Article CAS PubMed Google Scholar
• Su, I. H. et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nature Immunol. 4, 124–131 (2003).
  Article CAS Google Scholar
• Score, J. et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 119, 1208–1213 (2012).
  Article CAS PubMed Google Scholar
• Brecqueville, M. et al. Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer J. 1, e33 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506–510 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157–163 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Lessard, J. et al. Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev. 13, 2691–2703 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Herrera-Merchan, A. et al. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nature Commun. 3, 623 (2012).
  Article CAS Google Scholar
• Le Beau, M. M. et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 88, 1930–1935 (1996).
  CAS PubMed Google Scholar
• Guglielmelli, P. et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 118, 5227–5234 (2011).
  Article CAS PubMed Google Scholar
• Park, I. K. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302–305 (2003).
  Article CAS PubMed Google Scholar
• Oguro, H. et al. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. J. Exp. Med. 209, 445–454 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Scheuermann, J. C. et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465, 243–247 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Abdel-Wahab, O. et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25, 1200–1202 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Abdel-Wahab, O., Kilpivaara, O., Patel, J., Busque, L. & Levine, R. L. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia 24, 1656–1657 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Metzeler, K. H. et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 118, 6920–6929 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Aravind, L. & Iyer, L. M. The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications. Cell Cycle 11, 119–131 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Abdel-Wahab, O. et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (in the press).
• Fisher, C. L. et al. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115, 38–46 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Abdel-Wahab, O. et al. ASXL1 mutations promote myeloid transformation through inhibition of PRC2-mediated gene repression. Blood (ASH Annual Meeting Abstracts) 118, 405 (2011).
  Google Scholar
• Wiesner, T. et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genet. 43, 1018–1021 (2011).
  Article CAS PubMed Google Scholar
• Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genet. 43, 1022–1025 (2011).
  Article CAS PubMed Google Scholar
• Krivtsov, A. V. & Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nature Rev. Cancer 7, 823–833 (2007). An excellent review on MLL-associated leukaemias and related epigenetic biology.
  Article CAS Google Scholar
• Tefferi, A., Levine, R. L. & Kantarjian, H. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms. Biol. Blood Marrow Transplant. 15, 114–119 (2009).
  Article PubMed Google Scholar
• Dawson, M. A. et al. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin. Nature 461, 819–822 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, F. et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 19, 283–294 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Griffiths, D. S. et al. LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nature Cell Biol. 13, 13–21 (2011).
  Article CAS PubMed Google Scholar
• de The, H. & Chen, Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature Rev. Cancer 10, 775–783 (2010).
  Article CAS Google Scholar
• Licht, J. D. et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85, 1083–1094 (1995).
  CAS PubMed Google Scholar
• Boukarabila, H. et al. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev. 23, 1195–1206 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Villa, R. et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11, 513–525 (2007).
  Article CAS PubMed Google Scholar
• Dash, A. B. et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc. Natl Acad. Sci. USA 99, 7622–7627 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ito, T. et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 466, 765–768 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kharas, M. G. et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nature Med. 16, 903–908 (2010).
  Article CAS PubMed Google Scholar
• Grossmann, V. et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 25, 557–560 (2011).
  Article CAS PubMed Google Scholar
• Boultwood, J. et al. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia 24, 1139–1145 (2010).
  Article CAS PubMed Google Scholar
• Makishima, H. et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 117, e198–e206 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Tefferi, A. et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with _JAK2_V617F. Leukemia 26, 475–480 (2012).
  Article CAS PubMed Google Scholar
• Roche-Lestienne, C. et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia 25, 1661–1664 (2011).
  Article CAS PubMed Google Scholar
• Bocker, M. T. et al. Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA cluster. Nature Commun. 3, 818 (2012).
  Article CAS Google Scholar
• Tefferi, A. et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23, 905–911 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Abdel-Wahab, O. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114, 144–147 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Stegelmann, F. et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25, 1217–1219 (2011).
  Article CAS PubMed Google Scholar
• Abdel-Wahab, O. et al. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25, 1219–1220 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Tefferi, A. et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24, 1302–1309 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Green, C. L. et al. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116, 2779–2782 (2010).
  Article CAS PubMed Google Scholar
• Green, C. L. et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118, 409–412 (2011).
  Article CAS PubMed Google Scholar
• Challen, G. A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genet. 44, 23–31 (2011).
  Article CAS PubMed Google Scholar
• Walter, M. J. et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25, 1153–1158 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Grossmann, V. et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 25, 877–879 (2011).
  Article CAS PubMed Google Scholar
• Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66–78 (2011).
  CAS PubMed PubMed Central Google Scholar
• Dorrance, A. M. et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J. Clin. Invest. 116, 2707–2716 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Dohner, K. et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J. Clin. Oncol. 20, 3254–3261 (2002).
  Article CAS PubMed Google Scholar
• Slovak, M. L. et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96, 4075–4083 (2000).
  CAS PubMed Google Scholar
• Super, H. J. et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 82, 3705–3711 (1993).
  CAS PubMed Google Scholar